Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04941521 · ClinicalTrials.gov registry record · Phase 1
Exenatide for Treating Cocaine Use Disorder
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04941521: Completed Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
NCT04941521 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04941521, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information about whether exenatide (Bydureon) may be safe and helpful as a medication treatment for individuals who want to stop using cocaine. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes, it has not been approved by the FDA to treat cocaine use; therefore, it is called an investigational drug.
Primary Outcome
Treatment completion will be assessed by attendance at the end-of-treatment timepoint.
Interventions
- DRUG Exenatide 2 mg [Bydureon]
- BEHAVIORAL Drug Counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2021-11-17 |
| Phase | Phase 1 |
What the finished NCT04941521 record still lists
NCT04941521 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Exenatide 2 mg [Bydureon] is the first listed.
NCT04941521 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04941521 about?
NCT04941521 is a clinical study titled "Exenatide for Treating Cocaine Use Disorder". The purpose of this study is to collect information about whether exenatide (Bydureon) may be safe and helpful as a medication treatment for individuals who want to stop using cocaine. Although exenatide (Bydureon) is approved by the Food and Drug Administration (FDA) for the treatment of type 2 di...
What is the current status of trial NCT04941521?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2021-06-24. Estimated completion is 2021-11-17.
What interventions are being tested in trial NCT04941521?
The interventions under investigation include: Exenatide 2 mg [Bydureon] (DRUG), Drug Counseling (BEHAVIORAL).
Who is sponsoring clinical trial NCT04941521?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04941521's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI